Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Ethics Forum: Prescribing Teratogenic Medications to Adolescents Can Raise Confidentiality, Ethical Concerns

Karen B. Onel, MD, & Melissa Tesher, MD  |  Issue: September 2016  |  September 8, 2016

Specific laws determining an adolescent’s right to confidentiality in medical situations vary by state, and it’s important physicians be aware of the regulations specific to their region of practice. Each state has provisions allowing adolescents to legally consent to medical care in certain situations, including emergencies, pregnancy-related care, STDs and HIV infection, contraceptive care, substance abuse and mental health care.1 However, a right to consent does not guarantee confidential or accessible care.

In this case, the patient’s health insurance is provided by her parents. If she uses the insurance to pay for contraception, the billing process would likely generate an explanation of benefits report, which would be mailed to her parents, thus disclosing sensitive information.2

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Title X (& Its Limitations)

In the U.S., many young people can independently access reasonably priced contraceptive care. The Title X publicly funded family planning program was enacted in 1970 with broad bipartisan support and signed into law by President Richard Nixon. Title X provides federal funds for family planning clinics, which are required to provide care regardless of patients’ ability to pay. For individuals with incomes above the poverty level, fees for service are based on a sliding scale.3

Title X clinics are present in every state. However, the accessibility of these clinics is variable and may be more limited in areas with widely dispersed populations due to transportation barriers.4

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Rheumatologists who frequently prescribe teratogenic medications should acquire familiarity with family planning laws and resources in their region. Confidential, low-cost contraceptive services broadly enable all physicians to provide necessary medical care and are particularly essential for vulnerable populations, including adolescents. In the case above, if confidential family planning services are inaccessible to the patient, the physician will be unable to provide care without contradicting at least one of the central principles of medical ethics: autonomy, beneficence, non-maleficence and justice.

Challenging Choices

In the absence of accessible contraceptive care for the patient in the case above, the rheumatologist might consider changing her immune suppressant from mycophenolate mofetil to azathioprine, which poses less risk during pregnancy.5 Although this approach reduces the risk of teratogenic effects (should the patient unexpectedly become pregnant), beneficence is compromised because the physician would not ordinarily consider changing medications when the patient’s current treatment is highly effective. Moreover, to avoid violating confidentiality, the rheumatologist might be in the awkward position of providing the patient’s parents a false, or at least disingenuous, rationale for the change in medication.

Page: 1 2 3 4 | Single Page
Share: 

Filed under:Ethics Tagged with:AdolescentsconfidentialityEthicspatient carePractice Managementrheumatologistteratogenic medication

Related Articles
    AndreyCherkasov / Shutterstock.com

    Rheumatic Disease Does Not Preclude Pregnancy

    November 9, 2017

    Preconception planning is essential to help women with autoimmune disease have optimal pregnancy outcomes. Unplanned pregnancy can also negatively impact disease course in some patients. Yet many rheumatologic patients of childbearing age do not receive adequate contraception or prepregnancy education and counseling. Rheumatologists must work collaboratively with other healthcare providers to make sure rheumatic patients…

    A Better Family Plan

    October 1, 2007

    How to minimize the risks of pregnancy for women with SLE

    Improved Family Planning Counseling Needed

    May 18, 2018

    In the U.S. today, approximately 45% of pregnancies are unintended or unplanned.1 Although this rate is considerably lower than in the past, women with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) or inflammatory myopathies tend to have better pregnancy outcomes if their disease is well controlled when they conceive. In addition, women taking certain medications…

    Rheumatologists Should Discuss with Patients Use of Immunomodulatory Agents During Pregnancy

    November 16, 2016

    The decision to continue or discontinue immunomodulatory medications during pregnancy is a difficult one for both patients and physicians. On the one hand, when left untreated, rheumatic conditions can cause harm to an unborn child, as well as to the pregnant mother. On the other hand, medications can be harmful to a developing fetus. In…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences